Compare BIO-TECHNE Corp (TECH) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Global X Uranium ETF — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while Global X Uranium ETF trades at $45. The key difference: BIO-TECHNE Corp pays a 0.44% dividend while Global X Uranium ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals.
| TECH | URA | |
|---|---|---|
Market Cap | $11.24B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $72.29 | $61.81 |
52-Week Low | $43.31 | $36.45 |
Enterprise Value | $11.32B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
URA, the Global X Uranium ETF, trades at $44.91, up 3.96% in the past 24 hours. The ETF shows strong technical momentum with bullish signals from moving averages and oscillators, though the 6-day RSI at 92.80 indicates potential overbought conditions. Recent news highlights significant government support for nuclear energy, including a $17.5 billion commitment to new reactors and a landmark US-Saudi atomic deal, creating positive sentiment around uranium demand.
The outlook for URA remains positive due to growing nuclear energy adoption driven by AI power demands and supportive government policies. Key risks include ETF expense ratios and uranium price volatility. Analyst sentiment is generally bullish, with several recent articles recommending URA as a buy opportunity following its recent correction, citing long-term contract pricing improvements for uranium producers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
